How did Jennifer Doudna, Emmanuelle Charpentier, and Feng Zhang contribute to CRISPR technology?
In the field of biotechnology, Jennifer Doudna, Emmanuelle Charpentier, and Feng Zhang have made foundational contributions to CRISPR technology, which allows for precise gene editing.
-
Jennifer Doudna and Emmanuelle Charpentier: In 2012, these researchers discovered that the type II CRISPR-Cas9 system could be adapted into a versatile molecular tool. They found that guide RNA sequences could be modified to direct the Cas9 enzyme to specific DNA targets, enabling efficient and accurate genome engineering. For this development, which transformed the landscape of biochemistry and medicine, they were awarded the 2020 Nobel Prize in Chemistry.123
-
Feng Zhang: In 2015, Zhang and his colleagues expanded the CRISPR toolkit by developing a version of the technology using the nuclease Cpf1 instead of Cas9. This alternative offers different functional advantages, such as requiring only a single guide RNA and creating staggered cuts in DNA. Zhang also contributed to the development of other tools, including CRISPR-Cas13 systems designed to target RNA.2
While these advancements offer immense potential to treat human disease, they also necessitate a strong commitment to ethical responsibility, particularly regarding the risks of unintended genetic alterations and the moral implications of germ-line editing.12